I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| abnormal cell | 4 studies | 23% ± 5% | |
| oligodendrocyte precursor cell | 4 studies | 27% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| abnormal cell | 4 studies | 23% ± 5% | |
| oligodendrocyte precursor cell | 4 studies | 27% ± 9% |
Insufficient scRNA-seq data for expression of LYPD1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 99% | 661.25 | 2616 / 2642 | 96% | 15.56 | 679 / 705 |
| ovary | 10% | 24.69 | 18 / 180 | 97% | 62.34 | 415 / 430 |
| kidney | 72% | 114.33 | 64 / 89 | 5% | 0.23 | 45 / 901 |
| pancreas | 40% | 56.41 | 132 / 328 | 35% | 1.58 | 63 / 178 |
| intestine | 50% | 106.40 | 481 / 966 | 5% | 0.19 | 24 / 527 |
| skin | 0% | 0.24 | 5 / 1809 | 51% | 4.65 | 241 / 472 |
| lung | 11% | 9.37 | 61 / 578 | 22% | 1.11 | 249 / 1155 |
| uterus | 4% | 22.69 | 7 / 170 | 27% | 2.56 | 123 / 459 |
| liver | 3% | 6.81 | 7 / 226 | 25% | 1.87 | 102 / 406 |
| esophagus | 14% | 17.85 | 197 / 1445 | 10% | 0.52 | 18 / 183 |
| adrenal gland | 7% | 6.97 | 17 / 258 | 15% | 1.63 | 34 / 230 |
| bladder | 5% | 2.71 | 1 / 21 | 10% | 0.39 | 51 / 504 |
| thymus | 7% | 6.18 | 47 / 653 | 7% | 0.55 | 41 / 605 |
| tonsil | 0% | 0 | 0 / 0 | 9% | 0.24 | 4 / 45 |
| stomach | 5% | 5.59 | 18 / 359 | 4% | 0.12 | 11 / 286 |
| breast | 3% | 6.17 | 14 / 459 | 4% | 0.18 | 46 / 1118 |
| lymph node | 0% | 0 | 0 / 0 | 7% | 0.61 | 2 / 29 |
| prostate | 2% | 1.42 | 5 / 245 | 1% | 0.01 | 3 / 502 |
| adipose | 2% | 2.31 | 29 / 1204 | 0% | 0 | 0 / 0 |
| heart | 2% | 1.63 | 13 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.05 | 1 / 80 |
| muscle | 1% | 1.06 | 9 / 803 | 0% | 0 | 0 / 0 |
| spleen | 1% | 0.58 | 2 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 1% | 0.56 | 9 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001662 | Biological process | behavioral fear response |
| GO_0095500 | Biological process | acetylcholine receptor signaling pathway |
| GO_1903077 | Biological process | negative regulation of protein localization to plasma membrane |
| GO_0072659 | Biological process | protein localization to plasma membrane |
| GO_0007271 | Biological process | synaptic transmission, cholinergic |
| GO_0035094 | Biological process | response to nicotine |
| GO_0098552 | Cellular component | side of membrane |
| GO_0045202 | Cellular component | synapse |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0033130 | Molecular function | acetylcholine receptor binding |
| GO_0030550 | Molecular function | acetylcholine receptor inhibitor activity |
| Gene name | LYPD1 |
| Protein name | Ly6/PLAUR domain-containing protein 1 (Putative HeLa tumor suppressor) (PHTS) LY6/PLAUR domain containing 1 |
| Synonyms | PSEC0181 Lynx2 UNQ3079/PRO9917 LYPDC1 |
| Description | FUNCTION: Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety. . |
| Accessions | Q8N2G4 ENST00000345008.6 [Q8N2G4-4] ENST00000449209.1 ENST00000397463.3 [Q8N2G4-1] F8WD77 |
